Lumateperone (ITI-007) is an antagonist of the 5-HT2A receptor with a Ki of 0.54 nM. It has anti-cancer activity and can also be used in the study of psychiatric disorders such as schizophrenia.

 

Brand: BCM

 

Target: 5-HT Receptor

 

Signaling Pathways: GPCR/G Protein; Neuroscience

 

In Vivo: ITI-722 was evaluated in the rat quipazine head twitch model induced by quipazine which is a 5-HT2A agonist, ITI-722 have ED50 values of 0.12 mg.

 

Boiling Point: 556.4±50.0 °C(Predicted)

 

pKa: 9.10±0.20(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F  

 

InChIKey: HOIIHACBCFLJET-SFTDATJTSA-N  

 

InChI: InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1

 

Attribute
[Chem Name]	1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one
[Synonym]	Lumateperone; ITI-007
[CAS No.]	313368-91-1
[MDL No.]	MFCD28502161
[Formula]	C24H28FN3O
[Molecular]	393.5
[Form]	Liquid
[Storage]	Stored at -20°C

Goods Tag